EUVIMEDEUVIMED entdecken
Open Access

Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database

Prashanth Ashok Kumar iD, Dongliang Wang, Danning Huang, Abirami Sivapiragasam iD

JCO Precision Oncology · 2024

DOI: 10.1200/po.23.00390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Prashanth Ashok Kumar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Upstate Cancer Center, Upstate University Hospital, Syracuse, NY. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Results from the TAILORx trial revealed that the use of adjuvant chemotherapy along with endocrine therapy had no survival advantage in patients with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2–negative (HER2–), node-negative (N0) breast cancer (BC) with an intermediate (11-25) 21-gene recurrence score (RS) in the overall population. However, in patients under age 50 years, adjuvant chemotherapy demonstrated a progression-free survival benefit when the RS ranged from 16-25. We studied this cohort with the population-based national database. METHODS The 2010-2018 National Cancer Database was used to include patients with BC age 18-50 years, N0, M0, RS 16-25, ER+/progesterone receptor±, and HER2–. Patients were divided into two groups on the basis of adjuvant chemotherapy use, and the survival between them was compared. RESULTS Adjuvant chemotherapy use was noted in 4,808/15,792 (30.45%) patients. Median RS was 18 and 21 in patients without and with adjuvant chemotherapy, respectively. Factors associated with adjuvant chemotherapy use were higher T stage, poor and moderately differentiated tumors, age

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansMiddle AgedAdolescentYoung AdultAdultFemaleRetrospective StudiesMastectomyErb-b2 Receptor Tyrosine KinasesPrognosisReceptors, EstrogenHormonesChemotherapy, Adjuvant

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenHormones

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Upstate Cancer Center, Upstate University Hospital, Syracuse, NY.
  • Department of Public Health and Preventive Medicine, Upstate University Hospital, Syracuse, NY.
  • Hollings Cancer Center, Medical University of South Carolina, Charleston, SC.

ORCID-Profile: Prashanth Ashok Kumar, Abirami Sivapiragasam

Zitieren

APA

Ashok Kumar, P., Wang, D., Huang, D., & Sivapiragasam, A. (2024). Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database. JCO Precision Oncology. https://doi.org/10.1200/po.23.00390

Vancouver

Ashok Kumar P, Wang D, Huang D, Sivapiragasam A. Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database. JCO Precision Oncology. 2024. doi:10.1200/po.23.00390

BibTeX
@article{AshokKumar2024,
  author = {Ashok Kumar, Prashanth and Wang, Dongliang and Huang, Danning and Sivapiragasam, Abirami},
  title = {Adjuvant Chemotherapy in Premenopausal Patients With Hormone-Positive Breast Cancer With a Recurrence Score of 16-25: A Retrospective Analysis Using the National Cancer Database},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.23.00390}
}
Kostenlos starten →